Suchergebnisse - "Fevery, Bart"

PubPharm (36)

1

Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults

enthalten in: Antiviral therapy | 2021

von Gane, E. | Pastagia, M. | Schwertschlag, U. | +12

2

JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis : OMEGA-1

enthalten in: Hepatology (Baltimore, Md.) | 2019

von Zeuzem, S. | Bourgeois, S. | Greenbloom, S. | +19

3

JNJ‐4178 (AL‐335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus‐Infected Patients Without Cirrhosis : OMEGA‐1

enthalten in: Hepatology | 2019

von Zeuzem, S. | Bourgeois, S. | Greenbloom, S. | +18

4

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

enthalten in: Virology journal | 2018

von Zoulim, F. | Moreno, C. | Lee, S. | +9

5

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

enthalten in: Virology journal | 2018

von Zoulim, F. | Moreno, C. | Lee, S. | +9

6

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

enthalten in: Virology journal | 2018

von Zoulim, F. | Moreno, C. | Lee, S. | +9

7

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients : an open-label, rollover study

enthalten in: BMC infectious diseases | 2017

von Gane, E. | DeJesus, E. | Janczewska, E. | +15

8

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

enthalten in: BMC infectious diseases | 2017

von Gane, E. | DeJesus, E. | Janczewska, E. | +15

9

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

enthalten in: BMC infectious diseases | 2017

von Gane, E. | DeJesus, E. | Janczewska, E. | +15

10

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis : A phase 3 study (OPTIMIST-2)

enthalten in: Hepatology (Baltimore, Md.) | 2016

von Lawitz, E. | Matusow, G. | DeJesus, E. | +17

CommentIn: Hepatology. 2016 Aug;64(2):330-2. - PMID 26992027